Clinical Trials Directory

Trials / Completed

CompletedNCT03816904

Involvement of SK3 Calcium Channel in Taxane Neuropathy

Status
Completed
Phase
Study type
Observational
Enrollment
97 (actual)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. No preventive or symptomatic treatment has been shown to be effective. Its pathophysiology is poorly known and probably multifactorial. A possible mechanism would be mediated by the activation of the SK3 calcium channel: a retrospective study carried out at the University Hospital of Tours (Carina RUA) found a significant association between the number of CAG triplets in the KCNN3 gene coding for the SK3 channel and the appearance of a taxane neuropathy.

Detailed description

Patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer, will be offered the study. The mode of administration of chemotherapy and the usual follow-up will not be modified by the protocol The determination of the SK3 status will be made from an additional tube collected during a collection as part of the treatment at the first arrival in a day hospital (no more blood tests). Blood sample of 7mL. Shipments and analyzes of samples in Tours in the pharmacogenetics laboratory under the responsibility of Dr. BARIN-LE GUELLEC. This study is non-invasive, without impact on the therapeutic management. The result of the polymorphism of SK3 will not be indicated in the record, so as not to influence the follow-up of the treatment and to allow an evaluation of the occurrence of peripheral neuropathy in blindness of the number of repetitions of the CAG triplet of the KCNN3 gene.

Conditions

Interventions

TypeNameDescription
OTHERBlood samplesBlood samples before the introduction of chemotherapy

Timeline

Start date
2019-02-06
Primary completion
2020-06-12
Completion
2020-06-12
First posted
2019-01-25
Last updated
2021-04-28

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03816904. Inclusion in this directory is not an endorsement.